Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration
The collaboration will focus on advancing the targeted use of LP-184 in defined subtypes of GBM and clarifying the most promising clinical applications for the drug candidate. The goal of the collaboration is to utilize state of art laboratory and animal models of GBM as well as PDXs and neurospheres to precisely characterize the efficacy along with the CNS biovaiability and the PK/PD of the drug candidate. This will help streamline a clinically ready program with the most biologically relevant and robust genomic or biomarker signature and dosage and regimens for treatment of GBMs. By having a gene signature that can be used in identifying patients that have the potential for the highest response, Lantern can potentially accelerate future clinical trials and shorten the time to achieving patient benefit for GBM patients.